374107-87-6

Upstream product

• 110-15-6 succinic acid 
• 1708-40-3 2-phenyl-[1,3]dioxan-5-ol 

Downstream Products

• 374107-88-7 [G₁]-PGLSA-bzld 
• 915790-47-5 succinic acid bis-[2-(2-benzyloxy-benzoyloxy)-1-(2-benzyloxy-benzoyloxymethyl)-ethyl] ester 
• 915790-48-6 succinic acid bis-[2-(2-hydroxy-benzoyloxy)-1-(2-hydroxy-benzoyloxymethyl)-ethyl] ester 

Relevant academic research and scientific papers

LOW-SWELLING HYDROGEL SEALANTS FOR WOUND REPAIR

One aspect of the present invention relates to a sealant comprising dendrimeric macromolecules that form a hydrogel. In certain instances, the sealants of the invention comprise a hydrogel that swells less than about 400 wt% upon hydration. In certain instances, the sealants of the present invention further comprise a pharmaceutical agent, such as an antibiotic, antimicrobial agent, or antiinflammatory agent. The sealants of the present invention may be used to treat a wound on a patient that is topical or in vivo. In addition, the sealants of the present invention can act as a barrier to bacteria and other organisms. Another aspect of the present invention relates to a method of sealing a wound on a patient comprising the steps of applying an effective amount of a dendrimeric compound to a wound on a patient and treating the dendrimeric compound with a polymerization agent. Another aspect of the present invention relates to a method of sealing a wound on a patient comprising the steps of treating a dendrimeric compound with a polymerization agent to form a repair agent, and applying the repair agent to a wound on a patient. Another aspect of the present invention relates to a kit for sealing a wound comprising a polymerizable dendrimeric compound that forms a hydrogel and a system for delivering the polymerizable dendrimeric compound to a wound on a patient.

METHOD OF PREPARING DENDRITIC DRUGS

Synthetic design of drug-incorporated novel dendrimer structures for quantitatively controlled drug delivery. The dendritic drugs have better control and thus a quantitative drug release can be obtained. There are no prior art dendritic drugs that control release both sequentially and quantitatively like the dendritic drugs disclosed herein. The dendritic drugs are formed by incorporating multiple same type drug units or more than two different drug types into a dendritic cascade structure to form a dendrimer drug.

Synthesis of salicylate dendritic prodrugs

A small drug molecule, salicylic acid, has been converted into well-defined dendritic macromolecules. The mono-disperse nature of these materials may be clearly shown by NMR and GPC. A third generation salicylic acid dendrimer contains sixty salicylic aci